Discovery of 4-Aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 Inhibitors. Part I: Optimization of in Vitro Potencies and Pharmacokinetic Properties-Reference-Cited by-同舟云学术

Discovery of 4-Aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 Inhibitors. Part I: Optimization of in Vitro Potencies and Pharmacokinetic Properties

Published:2014-05-07 Issue:10 Volume:57 Page:4098-4110
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lee Ying-Shuan E.¹,Chuang Shih-Hsien¹,Huang Lynn Y. L.²,Lai Chun-Liang¹,Lin Yu-Hsiang¹,Yang Ju-Ying¹,Liu Chia-Wei¹,Yang Sheng-chuan¹,Lin Her-Sheng¹,Chang Chia-chi²,Lai Jun-Yu³,Jian Pei-Shiou³,Lam King¹,Chang Jia-Ming¹,Lau Johnson Y. N.²,Huang Jiann-Jyh¹³

Affiliation:

1. Development Center for Biotechnology, No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei City 22180, Taiwan

2. Taivex Therapeutics Corporation, 17th Floor, No. 3, Yuanqu Street, Nangang District, Taipei City 115, Taiwan

3. Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm401990s

Reference35 articles.

1. Recruitment of the human Cdt1 replication licensing protein by the loop domain of Hec1 is required for stable kinetochore–microtubule attachment